MBRX - Moleculin Biotech, Inc.

QQQ $ 480.15 $ -1.01 (-0.21 %)

DIA $ 408.54 $ -0.55 (-0.13 %)

SPY $ 558.65 $ -0.91 (-0.16 %)

TLT $ 98.68 $ 0.78 (0.8 %)

GLD $ 232.46 $ 0.85 (0.37 %)

Previous Close

$ 2.57

Open

$ 2.55

Bid

$ 2.51 x 100

Ask

-- x --

Day's Range

$ 2.52 - $ 2.61

52 Week Range

$ 2.12 - $ 15.75

Volume

77,150

Average Volume

Market Cap

6.58M

Beta (5Y Monthly)

$ 1.39

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-10-2024	03-31-2024	10-Q
3	03-22-2024	12-31-2023	10-K
4	11-13-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-10-2023	03-31-2023	10-Q
7	03-22-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-12-2022	06-30-2022	10-Q
10	05-11-2022	03-31-2022	10-Q
11	03-24-2022	12-31-2021	10-K
12	11-10-2021	09-30-2021	10-Q
13	08-11-2021	06-30-2021	10-Q
14	05-12-2021	03-31-2021	10-Q
15	03-24-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	08-12-2020	06-30-2020	10-Q
18	05-11-2020	03-31-2020	10-Q
19	03-19-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-16-2019	06-30-2019	10-Q
22	05-13-2019	03-31-2019	10-Q
23	02-21-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q
25	08-10-2018	06-30-2018	10-Q
26	05-14-2018	03-31-2018	10-Q
27	03-28-2018	12-31-2017	10-K
28	11-13-2017	09-30-2017	10-Q
29	08-11-2017	06-30-2017	10-Q
30	05-12-2017	03-31-2017	10-Q
31	04-03-2017	12-31-2016	10-K
32	11-21-2016	09-30-2016	10-Q
33	08-15-2016	06-30-2016	10-Q
34	06-16-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Moleculin Biotech shares are trading lower...
08/16/2024 12:10:46

Moleculin Biotech Announces Pricing Of Pub...
08/16/2024 12:04:47

Warrants Exercisable Upon Shareholder Approval With Series A Expiring In 2 Years And Series B In 5 Years, Subject To Interim An...

Moleculin Biotech Q2 EPS $(1.70) Beats $(2...
08/14/2024 12:12:04

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(2...

$moleculin-announces-plans-for-miracle-adaptive-phase-3-clinical-trial-designed-for-possible-accelerated-approval-of-annamycin-in-combination-with-cytarabine-for-the-treatment-of-relapsed-or-refractory-aml$

Moleculin Announces Plans For MIRACLE Adap...
08/01/2024 12:36:43

Based on an encouraging discussion in the End of Phase 1B/2 Meeting with FDA the Company plans to:Proceed with a pivotal, adapt...

$moleculin-biotech-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-as-both-first-line-therapy-and-for-subjects-who-are-refractory-to-or-relapsed-after-induction-therapy$

Moleculin Biotech Completes End Of Phase 2...
07/10/2024 12:32:36

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ...

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
06/14/2024 12:06:22

Moleculin Reports Additional Preliminary I...
06/14/2024 12:05:40

– 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of res...

Moleculin Biotech Files For Mixed Shelf Of...
06/07/2024 21:18:19

- SEC Filing

Moleculin Commences NIH-Funded Phase 2 Cli...
05/15/2024 12:40:04

– Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin– Trial combi...

Moleculin Biotech Q1 EPS $(2.02) Beats $(3...
05/10/2024 21:09:42

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3...

Moleculin Biotech Received Issue Notificat...
05/09/2024 12:43:26

Patent, once issued, will provide composition protection through 2040, with potential for additional term extensionAnnamycin is...

Moleculin Reports Higher AML Complete Remi...
05/07/2024 13:02:30

Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1st and 2nd line AML subjects (N=13)Ful...

Moleculin Announces Formation Of Scientifi...
05/01/2024 13:01:27

12 Health Care Stocks Moving In Friday's P...
04/26/2024 12:06:32

European Medicines Agency Grants Orphan Dr...
04/18/2024 12:36:14

Roth MKM Maintains Buy on Moleculin Biotec...
04/12/2024 16:24:03

Roth MKM analyst Jonathan Aschoff maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $40 price target.

Moleculin Presents Data For Anthracycline
04/10/2024 12:34:09

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/08/2024 20:31:20

Moleculin Received U.S. Patent Issue Notif...
03/27/2024 13:06:48

Maxim Group Maintains Buy on Moleculin Bio...
03/26/2024 13:24:15

Maxim Group analyst Jason McCarthy maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $45...